These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30286726)

  • 1. Impact of the 10-valent pneumococcal conjugate vaccine on antimicrobial prescriptions in young children: a whole population study.
    Eythorsson E; Sigurdsson S; Hrafnkelsson B; Erlendsdóttir H; Haraldsson Á; Kristinsson KG
    BMC Infect Dis; 2018 Oct; 18(1):505. PubMed ID: 30286726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial.
    Palmu AA; Jokinen J; Nieminen H; Rinta-Kokko H; Ruokokoski E; Puumalainen T; Borys D; Lommel P; Traskine M; Moreira M; Schuerman L; Kilpi TM
    Lancet Infect Dis; 2014 Mar; 14(3):205-12. PubMed ID: 24287186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in All-Cause Acute Otitis Media in Children <3 Years of Age in Primary Care Following Vaccination With 10-Valent Pneumococcal Haemophilus influenzae Protein-D Conjugate Vaccine: A Whole-Population Study.
    Sigurdsson S; Eythorsson E; Hrafnkelsson B; Erlendsdóttir H; Kristinsson KG; Haraldsson Á
    Clin Infect Dis; 2018 Sep; 67(8):1213-1219. PubMed ID: 29617959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the 10-valent pneumococcal conjugate vaccine on hospital admissions in children under three years of age in Iceland.
    Sigurdsson S; Eythorsson E; Erlendsdóttir H; Hrafnkelsson B; Kristinsson KG; Haraldsson Á
    Vaccine; 2020 Mar; 38(12):2707-2714. PubMed ID: 32063434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age.
    Karppinen S; Toivonen L; Schuez-Havupalo L; Teros-Jaakkola T; Waris M; Auranen K; Palmu AA; Peltola V
    Vaccine; 2019 May; 37(22):2935-2941. PubMed ID: 31027929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial.
    Palmu AA; Jokinen J; Nieminen H; Syrjänen R; Ruokokoski E; Puumalainen T; Moreira M; Schuerman L; Borys D; Kilpi TM
    Lancet Respir Med; 2014 Sep; 2(9):717-27. PubMed ID: 25127244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
    Palmu AA; Jokinen J; Borys D; Nieminen H; Ruokokoski E; Siira L; Puumalainen T; Lommel P; Hezareh M; Moreira M; Schuerman L; Kilpi TM
    Lancet; 2013 Jan; 381(9862):214-22. PubMed ID: 23158882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions.
    Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
    Hum Vaccin Immunother; 2022 Dec; 18(1):1942712. PubMed ID: 34319865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of Streptococcus pneumoniae in upper respiratory tract cultures and a decreased incidence of related acute otitis media following introduction of childhood pneumococcal conjugate vaccines in a Swedish county.
    Littorin N; Ahl J; Uddén F; Resman F; Riesbeck K
    BMC Infect Dis; 2016 Aug; 16(1):407. PubMed ID: 27514843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine in a cluster-randomised trial.
    Rinta-Kokko H; Palmu AA; Ruokokoski E; Nieminen H; Moreira M; Schuerman L; Borys D; Jokinen J
    PLoS One; 2022; 17(1):e0261750. PubMed ID: 34986178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial.
    Palmu AA; Jokinen J; Nieminen H; Rinta-Kokko H; Ruokokoski E; Puumalainen T; Moreira M; Schuerman L; Borys D; Kilpi TM
    Vaccine; 2018 Mar; 36(14):1816-1822. PubMed ID: 29503110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased Acute Otitis Media With Treatment Failure After Introduction of the Ten-valent Pneumococcal Haemophilus influenzae Protein D Conjugate Vaccine.
    Eythorsson E; Hrafnkelsson B; Erlendsdóttir H; Gudmundsson SA; Kristinsson KG; Haraldsson Á
    Pediatr Infect Dis J; 2018 Apr; 37(4):361-366. PubMed ID: 29278616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct and Indirect Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine Against Carriage in a Cluster Randomized Trial.
    Palmu AA; Toropainen M; Kaijalainen T; Siira L; Lahdenkari M; Nieminen H; Syrjänen RK; Kilpi TM; Jokinen J
    Pediatr Infect Dis J; 2017 Dec; 36(12):1193-1200. PubMed ID: 28737627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of the 10-valent pneumococcal conjugate vaccine among girls, boys, preterm and low-birth-weight infants - Results from a randomized, double-blind vaccine trial.
    Nieminen H; Rinta-Kokko H; Jokinen J; Puumalainen T; Moreira M; Borys D; Schuerman L; Palmu AA
    Vaccine; 2019 Jun; 37(28):3715-3721. PubMed ID: 31122856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact and cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the paediatric immunisation programme in Iceland-A population-based time series analysis.
    Eythorsson E; Ásgeirsdóttir TL; Erlendsdóttir H; Hrafnkelsson B; Kristinsson KG; Haraldsson Á
    PLoS One; 2021; 16(4):e0249497. PubMed ID: 33831049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial.
    Kilpi TM; Jokinen J; Puumalainen T; Nieminen H; Ruokokoski E; Rinta-Kokko H; Traskine M; Lommel P; Moreira M; Ruiz-Guinazu J; Borys D; Schuerman L; Palmu AA
    Vaccine; 2018 Sep; 36(39):5891-5901. PubMed ID: 30145098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of National Ten-Valent Pneumococcal Conjugate Vaccine Program on Reducing Antimicrobial Use and Tympanostomy Tube Placements in Finland.
    Palmu AA; Rinta-Kokko H; Nohynek H; Nuorti JP; Jokinen J
    Pediatr Infect Dis J; 2018 Jan; 37(1):97-102. PubMed ID: 29088026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Otitis media in children vaccinated during consecutive 7-valent or 10-valent pneumococcal conjugate vaccination schedules.
    Leach AJ; Wigger C; Andrews R; Chatfield M; Smith-Vaughan H; Morris PS
    BMC Pediatr; 2014 Aug; 14():200. PubMed ID: 25109288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States.
    Grijalva CG; Poehling KA; Nuorti JP; Zhu Y; Martin SW; Edwards KM; Griffin MR
    Pediatrics; 2006 Sep; 118(3):865-73. PubMed ID: 16950975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.